Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This phase II trial studies the side effects and best dose of propranolol when administered concurrently with SOC neoadjuvant CRT in patients with esophageal carcinoma, with a safety lead-in and dose expansion cohort. Patients who are already on β-blockers will receive standard of care CRT and will be considered separately as a single arm prospective cohort
Epistemonikos ID: 3af64d3edea9e33ab432a9ed19e4605c2064a802
First added on: May 08, 2024